Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
Terminated · Phase 1, Phase 2 · NCT05450562
Conditions: Neoplasm
At a glance
- Research payments reported, 2025
- $372,144
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 33
About the trial
- Sponsor
- Sanofi
- Tested
- SAR444200 (biological), Atezolizumab (biological)
- Dates
- Started 2022-09-20; completion 2025-12-22
- Results posted
- Not yet
This is Phase 1/Phase 2, open label, multiple cohort, first-in-human study to evaluate safety, PK, PDy and efficacy of SAR444200 as a monotherapy or in combination with other anti-cancer agents for participants aged at least 18 years with previously treated metastatic malignancies.
From ClinicalTrials.gov, last updated 2026-01-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $372,144 in research payments for this study in 2025 (18 payments).
Products named: Libtayo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Anthony B. El-khoueiry, M.D. Medical Oncology · Los Angeles, CA
- Deirdre J. Cohen, M.D. Hematology & Oncology · New York, NY
- Khaldoun Almhanna, MD, MPH Hematology & Oncology · Providence, RI
- Ecaterina E. Dumbrava, MD Medical Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Rhode Island Hospital, RI $181,958
- Keck Hospital of Usc, CA $108,241
- Ut MD Anderson Cancer Center $73,845
- Mount Sinai School of Medicine Psychiatry $8,100
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.